Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Renewi agrees takeover by Macquarie, shares jump

(Sharecast News) - Waste management firm Renewi shot higher on Thursday as it agreed to be bought by Australian investment firm Macquarie Asset Management in a £707m deal. Under the terms of the acquisition, Macquarie will pay 870p per share in cash. This is a premium of about 57% to the closing share price 27 November 2024, which was the last day before the start of the offer period.

Renewi has rejected several offers from Macquarie on the basis that they fundamentally undervalued the company, but said last November that it was "minded to recommend" the 870p a share proposal should a firm offer be made.

Chairman Ben Verwaayen said: "Renewi is a leader across Europe's recycling industry and is successfully delivering on its waste-to-product strategy. The offer represents not only a material premium for our shareholders, but also an opportunity with the support from Macquarie and BCI to further deliver on our strategy, to the benefit of all stakeholders, from employees to customers.

"We believe the consortium will be a strong steward of Renewi, building on our success to date, and we are consequently recommending shareholders vote in favour of the combination."

Martin Bradley, head of Infrastructure at Macquarie Asset Management in EMEA, said: "The European circular economy continues to advance rapidly, driven by policies that support a low-carbon, sustainable future; and long-term private capital can help to support this change.

"As a leading waste-to-product company, Renewi is well-positioned to lead in reshaping the waste market. Macquarie has been investing in and developing companies in the waste sector for more than 15 years and we look forward to partnering with Renewi in its journey as it focuses on becoming a European Leader in the Circular Economy. This strategic acquisition aligns with our commitment to innovation, enabling communities to achieve a sustainable future."

At 1240 GMT, Renewi was up 4.4% at 851.79p.

News of the takeover came alongside a third-quarter trading update in which Renewi said revenue from continuing operations rose 4.2% on the same period a year earlier to €1.3bn. This was "against a backdrop of continuing regional economic sluggishness, supported by higher volumes in Specialities and higher inbound prices in Commercial Waste," it said.

Underlying earnings before interest and tax ticked up 8.4% to €77.6m, with a strong contribution from Mineralz & Water and Specialities, together with lower SG&A costs.

Renewi said that while market conditions remain mixed, the benefits of its commercial and cost initiatives "underpin the continued expectation of solid progress" in FY25.

"We enter the final quarter with positive growth momentum which should enable the group to achieve a full year revenue performance in line with its previous expectations," it said. "Further productivity and cost initiatives are being implemented to mitigate, in part, the effect of the additional cost and market headwinds experienced in Q3, which are anticipated to persist in the remainder of the year."

The group said it remains committed to delivering on its medium-term targets of a high-single digit underlying EBIT margin and organic annual revenue growth of more than 5%.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.